

AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS

Please amend the allowed claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Claims 1-15 (canceled)

~~1~~ ~~16~~. (previously presented) A liquid polymeric composition for controlled release of eprinomectin consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and
- (c) at least one lipophilic solvent or a mixture of hydrophilic and lipophilic solvents, wherein the volume ratio of the hydrophilic and lipophilic solvents is from about 80:20 to about 5:95.

~~2~~ ~~17~~. (previously presented) The composition of claim ~~16~~ wherein the lipophilic solvent is triacetin.

~~12~~ ~~18~~. (previously presented) The composition of claim ~~16~~ wherein the hydrophilic solvent is N-methyl pyrrolidone.

~~3~~ ~~19~~. (previously presented) The composition of claim ~~17~~ wherein the hydrophilic solvent is N-methyl pyrrolidone.

~~8~~ ~~20~~. (previously presented) The composition of claim ~~17~~ consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less

and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

⁴
~~21.~~ (c) triacetin.
³
~~21.~~ (currently amended) The composition of claim ~~19~~ consisting essentially of:

(a) 1 to 10% of eprinomectin;
(b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

¹
~~21.~~ (c) ~~triacetin~~ N-methyl pyrrolidone and N-methyl pyrrolidone triacetin, wherein the volume ratio of the ~~triacetin~~ N-methyl pyrrolidone and N-methyl pyrrolidone triacetin is from about 80:20 to about 5:95.

⁹
~~22.~~ (previously presented) The composition of claim ~~20~~ wherein (a) consists essentially of about 5% eprinomectin.

⁵
~~23.~~ (previously presented) The composition of claim ~~21~~ wherein (a) consists essentially of about 5% eprinomectin.

¹⁰
~~24.~~ (previously presented) The composition of claim ~~22~~ wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

⁶
~~25.~~ (previously presented) The composition of claim ~~23~~ wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

¹¹
~~26.~~ (previously presented) The composition of claim ~~24~~ wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

⁷
~~27.~~ (previously presented) The composition of claim ~~25~~ wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

¹³
~~28.~~ (previously presented) A method for the controlled release of eprinomectin in a mammal which comprises injecting said mammal with the composition of any one of claims ~~16-27~~.

¹⁴
~~29.~~ (previously presented) The method of claim ~~28~~ wherein the mammal is a bovine.

G1
contd

¹⁵
~~30.~~ (previously presented) The method of claim ¹³~~28~~ wherein the mammal is an
ovine.

¹⁶
~~31.~~ (previously presented) The method of claim ¹³~~28~~ wherein the mammal is a
canine.--
